Clinical Trial Update: A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing apremilast for Epidermolysis Bullosa Simplex is currently recruiting at Centre Hospitalier Universitaire de Nice.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa Simplex

Drugs mentioned

• OTEZLA (apremilast)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Epidermolysis Bullosa Simplex, Genodermatosis | Phase 2 | Status: RECRUITING